Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the European Commission has granted marketing authorization for Multaq® (dronedarone ? 400mg Tablets) in all 27 European member states. This approval follows the European Commission positive opinion issued on September 25, 2009 by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicine [...] www.apothekersnieuws.nl/...on-for-patients-with-atrial-fibrillation/3852/ - 1 Dec 2009
Printen
Doorsturen